Blog

Global Breast Cancer Initiative Implementation Planning Workshop by WHO – City Cancer Challenge

City Cancer Challenge/LinkedIn

Nov 30, 2024, 23:26

Global Breast Cancer Initiative Implementation Planning Workshop by WHO – City Cancer Challenge

City Cancer Challenge shared a post on LinkedIn:

“Cali is at the forefront of a global movement as local and international leaders gather for the Global Breast Cancer Initiative (GBCI) Implementation Planning Workshop. Developed by the World Health Organization (WHO), the GBCI framework is being implemented at the city level by C/Can, empowering cities like Cali to transform breast cancer care.

Since joining C/Can in 2017, Cali has become a hub of innovation in cancer care. Now, the city is developing a Breast Cancer Action Plan (BCAP) tailored to its unique needs, aiming to improve early detection, diagnosis, and treatment. With breast cancer as the most diagnosed cancer among women worldwide, this initiative holds the power to save lives and inspire similar efforts across Latin America.

Learn how Cali is leading the fight against breast cancer and shaping a healthier future for women across the region.

A special thank you to all the experts and advocates driving this crucial work forward in Colombia and around the world! Your dedication is inspiring change. We’d like to extend our thank you to IFPMA for its convening role and to Amgen, AstraZeneca, Bristol Myers Squibb, and MSD who provided essential funding through which C/Can can operate the GBCI partnership.”

Breast Cancer

More posts featuring City Cancer Challenge.

America Amgen AstraZeneca BCAP Breast Cancer Breast Cancer care Bristol Myers Squibb Cali cancer cancer care City Cancer Challenge Colombia diagnosis GBCI GBCI partnership IFPMA international leaders MSD OncoDaily Oncology treatment WHO

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term